Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | GLI1 | P08151 | 1/20 | 0.33 |
| ▸ | GLI2 | P10070 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23465807 | 0.86 | — | — | |
| SCHEMBL18827461 | 0.80 | GLI1 (0.33) | CYP3A4GLI1GLI2 | |
| SCHEMBL10029417 | 0.75 | TSHR (0.34) | OPRM1TSHRCYP3A4GLI1GLI2 | |
| SCHEMBL21945407 | 0.74 | USP2 (0.32) | TSHRCYP3A4CYP2D6USP2ALDH1A1 | |
| SCHEMBL24638773 | 0.74 | TSHR (0.31) | TSHRCYP2D6USP2ALDH1A1HPGD | |
| SCHEMBL22275306 | 0.72 | TSHR (0.34) | OPRM1TSHR | |
| SCHEMBL24880548 | 0.72 | — | — | |
| SCHEMBL4837023 | 0.72 | — | — | |
| SCHEMBL23569915 | 0.71 | — | — | |
| SCHEMBL18126814 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2021102468-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-9850242-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD (JP) | 2017-12-26 | — | — | US | disclosed |
| US-20160339032-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9446046-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-9126999-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | OPRM1 2908/4885TSHR 659/4885GABRD 1107/4885 |
| US-20160339032-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | SSB, TLR8, TLR9 | OPRM1 3490/4885TSHR 1323/4885GABRD 2312/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | OPRM1 2908/4885TSHR 659/4885GABRD 1107/4885 |
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | OPRM1 2908/4885TSHR 659/4885GABRD 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.